Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

Preclinical Pipeline 545.4 Neuroendocrine Carcinoma Therapeutics- Clinical Pipeline by Mechanism of Action 555.5 Technology Trends Analytic Framework 555.6 Neuroendocrine Carcinoma Therapeutics - Key Late Stage Pipeline Drugs in Clinical Development 585.7 Molecule Profile for Key Late Stage Pipeline Drugs under Clinical Development 585.7.1 Avastin (bevacizumab) 585.7.2 Lutathera ([177Lutetium]-DOTA0-Tyr3-Octreotate) 595.7.3 Paseriotide (SOM 230) 605.7.4 Somatuline Autogel (lanreotide acetate) 615.8 Key Takeaway 616 Neuroendocrine Carcinoma Therapeutics - Clinical Trials Mapping 626.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 626.2 Clinical Trials by Phase 636.3 Clinical Trials by Trial Status 646.4 Prominent Sponsors 656.5 Top Companies Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials 677 Neuroendocrine Carcinoma Therapeutics- Strategic Assessment 687.1 Future Market Competition Scenario 688 Neuroendocrine Carcinoma Therapeutics - Future Players 708.1 Introduction 708.2 Company Profiles for the Promising Drugs 708.2.1 Advanced Accelerator Applications S.A 708.2.2 Novartis AG 718.2.3 F. Hoffmann-La Roche 738.2.4 Ipsen SA 748.3 Other Companies in the Neuroendocrine Carcinoma Therapeutics Market 769 Neuroendocrine Carcinoma Therapeutics- Licensing and Partnership Deals 7710 Neuroendocrine Carcinoma Therapeutics - Appendix 7910.1 Market Definitions 7910.2 Abbreviations 7910.3 Methodology 8010.3.1 Coverage 8110.3.2 Secondary Research 8110.3.3 Forecasting 8110.3.4 Primary Research 8310.3.5 Expert Panel Validation 8410.4 Contact Us 8410.5 Disclaimer 8410.6 Bibliography 84

List of Tables

Table 1: GEP-NETs WHO Classification 7Table 2:GEP-NETs Classification 8Table 3: Historical Prevalence for Neuroendocrine Carcinoma* for Seven Major Markets 9Table 4: Forecast Prevalence for Neuroendocrine Carcinoma* for Seven Major Markets 10Table 5: Symptoms of Pancreatic NETs/Islet Cell Tumors 12Table 6:Diagnosis Techniques by S
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Nanobiotechnology ... offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biochips and Microarrays ... offering. This report is an analysis ... The report starts with a description of technologies ... include array comparative genomic hybridization (CGH), copy number ...
(Date:9/2/2015)... 02, 2015 Research and ... Jain PharmaBiotech,s new report "Gene Therapy - Technologies, ... The markets for gene therapy are difficult to estimate ... and it is marketed in China ... the years 2014-2024. The estimates are based on epidemiology ...
(Date:9/2/2015)... ... 02, 2015 , ... Drug companies increasingly are adopting a ... reveals in its new report that the U.S. will generate the greatest demand ... the most market demand. , BCC Research examines plant-derived drugs in its ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... Development of Farletuzumab for Ovarian CancerAgreement Highlights Lonza,s ... Pa. and BASEL, Switzerland, May 19 Morphotek(R), ... America, and Lonza Group Ltd jointly announced today ... to support the development and manufacturing of a ...
... Therapeutic for IBD with Novel Mode of ActionMOUNTAIN ... Inc., today announced that data from the company,s ... Crohn,s disease Trial) Phase II/III clinical trial of ... will be presented in an oral session at ...
... to present Phase 2 data on perifosine for ... Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ... therapy and oncology, today announced that results supporting ... compound, AEZS-108, in prostate cancer, will be presented ...
Cached Biology Technology:Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 2Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 3Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting 2AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting 3
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... mammals arose in the Triassic period, over 225 million years ... as Morganucodon from England, Megazostrodon from ... differentiated teeth (incisors, canines, molars) and large brains and were ... make them stand apart from their reptile ancestors, and which ...
... 2013) When a woman becomes pregnant, she knows it ... the health of herself and the health of her baby. ... and the Eurpean Federation of Periodontology (EFP) urge pregnant women ... women with periodontal disease may be at risk of adverse ...
... United States there are millions of sports related concussions each ... fear of being benched trumps the fear of permanent brain ... diagnose concussions on the sidelines. , Researchers at San ... , A team led by Daniel Goble, an exercise and ...
Cached Biology News:Not the end of the world: Why Earth's greatest mass extinction was the making of modern mammals 2Expectant mothers' periodontal health vital to health of her baby 2Combating concussions 2Combating concussions 3
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
When added to StemSep T Cell Enrichment cocktail, human TCRab TAC is designed to deplete human TCRab from samples to isolate gd T cells....
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... The Eclipse C1 Plus is a ... highest-quality digital imaging with an ultra-compact and ... of the C1 Plusboost optical performance to ... acquisition.The system alsoincludes support for X and ...
Biology Products: